Director, International Digital Products & Experience Strategy

Pfizer • New York City, NY

9d • Hybrid

About The Position

The Director, International Digital Product & Experience Strategy is the international lens on Pfizer’s HCP and Consumer digital roadmaps. Reporting to the Head of Ecosystem Strategy, this role sits within the Ecosystem Strategy function and works across both surfaces to answer a single question: what should Pfizer be building for patients and HCPs in international markets that it is not building today, and where is the right to win. This is a strategy role, not a delivery or governance role, while it does not directly own product, platforms, or affiliate operations. Instead, it feeds international market needs, opportunities, regulatory realities, and capability constraints into the Surfaces leads (Consumer Products and HCP Products) who own the roadmaps and ship the product. Its value is in shaping what goes onto those roadmaps from a global perspective, so Pfizer’s digital surfaces are built for international markets by design rather than adapted for them after the fact. The role is deliberately influence-and-insight. Its authority comes from owning the international input into roadmap prioritization: a structured, standing voice in how surface roadmaps are sequenced, ensuring market-specific needs are weighed deliberately rather than discovered late as launch blockers. Over time the role weights toward HCP in line with international commercial priorities.

Requirements

• 8+ years in digital strategy, with deep expertise in patient- and HCP-facing digital products and experiences across international markets.
• Demonstrated ability to shape product direction through influence in a global, matrixed organization, translating market needs into roadmaps owned by others, rather than owning delivery directly.
• Strong command of the international regulatory and market-structure landscape affecting digital health (privacy, promotional compliance, data residency, market-specific constraints).
• Deep understanding of the evolving AI search and discoverability landscape (GEO, ChatGPT, Perplexity, AI Overviews) and its implications for pharmaceutical digital presence internationally.
• Proven ability to read market capability and readiness differences and turn them into actionable prioritization guidance.
• Cross-functional leadership fluency across marketing, medical, IT, data, UX, and compliance in a regulated industry.
• Bachelor's degree or equivalent required

Nice To Haves

• Pharmaceutical or healthcare experience, with familiarity with MLR compliance and international affiliate operating models.
• Experience across multiple markets or geographies, with a benchmarked view of what good looks like beyond a single organization.
• Comfort operating within a deliberately evolving organizational structure, as part of a transformation to lead in AI and build a fully connected international customer experience.
• Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.

Responsibilities

• Define where Pfizer has the right to win across international HCP and patient digital experiences, identifying unmet needs and market-specific gaps that the current roadmap does not address.
• Translate international patient and HCP journeys into a clear, prioritized set of needs and opportunities, feeding them into the Consumer and HCP roadmaps owned by the Surfaces leads.
• Move the international conversation from asset-driven (which sites do we have) to opportunity-driven (what should we build, where, and why), backed by a defensible view of market priority and potential.
• Surface international regulatory and market-structure realities (privacy, promotional rules, data residency, consent, market-specific AI and content rules) and bring them into roadmap prioritization deliberately and early.
• Act as the early-warning function for regulatory watchouts that a US-centered roadmap would otherwise miss, so global product decisions account for what is permissible and practical market by market.
• Provide the honest read on where key markets can and cannot absorb a given product, platform, or capability, accounting for affiliate maturity, infrastructure, channel mix, and local platform realities.
• Flag capability gaps and readiness differences before global bets are made, so the Surfaces leads sequence rollouts against real local readiness rather than an assumed-uniform market.
• Work with Global Media Team to define the AI discoverability strategy for international markets: how Pfizer shows up, and is trusted, in AI-generated answers (ChatGPT, Perplexity, Google AI Overviews, and equivalents) across different languages, surfaces, and market-specific platforms.
• Ensure international content and experiences are engineered to be cited by AI, not merely indexed, and set the international view on responsible AI presence that the Surfaces and Innovation teams build against.
• Own the international input into roadmap prioritization as a standing mechanism, holding a structured seat in the Consumer and HCP prioritization cadences so international needs are required input, not optional.
• Partner with the Surfaces leads, UX, and Operations to ensure international requirements survive the journey from strategy into what actually ships in markets, closing the gap between intent and local reality without owning the delivery itself.
• The balance of the role shifts deliberately over time in line with international commercial priorities: Through end of 2026, 50% Patient / 50% HCP. Weighted toward consolidating patient initiatives already in flight: establishing a clear process for launching patient websites across local, ICO, and Global teams; promoting shared design systems and platforms as common foundations; and getting international content GEO-ready so it is cited by AI, not just indexed.
• Begins contributing directly to HCP platforms as critical drivers of business performance.
• From January 2027, 65% HCP / 35% Patient. Shifts weight to HCP in clear alignment with international commercial priorities, while maintaining the patient foundations established in 2026.

Benefits

• 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution
• paid vacation, holiday and personal days
• paid caregiver/parental and medical leave
• health benefits to include medical, prescription drug, dental and vision coverage
• Relocation assistance may be available based on business needs and/or eligibility.

What This Job Offers

• Job Type: Full-time
• Career Level: Director